Spruce Biosciences Reports Q3 GAAP EPS Miss and Increased Cash Position
Spruce Biosciences (SPRB) reported third-quarter GAAP earnings per share of -$8.51, missing analyst expectations by $2.83. Despite the earnings miss, the company saw a significant increase in its liquidity position. As of September 30, 2026, Spruce Biosciences held $87.7 million in cash and cash equivalents, up from $48.9 million at the end of 2025. Management stated that current cash reserves are expected to be sufficient to fund planned operations and debt obligations through the second half of 2027.
Tickers: $SPRB
Topics: cash runway earnings report financial results GAAP EPS
Read the full article at Seeking Alpha
Part of the story Spruce Biosciences Reports Q3 GAAP EPS Miss and Increased Cash Position (3 articles)